Migra-Therapeutics

MIGRA-Therapeutics is a private, preclinical-stage biotech focused on overcoming a major hurdle in cancer treatment: delivering therapeutics effectively into dense, resistant solid tumors. The company's platform utilizes hyaluronic acid nanoparticles and protease-enabled systems to create stroma-penetrating delivery vehicles for both chemotherapy drugs and therapeutic cells like CAR-Ts. With foundational support from NIH SBIR grants and strong academic ties, MIGRA is advancing its lead candidate, MIGRA-NP01, towards IND-enabling studies for pancreatic cancer while seeking partnerships to broaden the platform's application.

A dual-component, stroma-penetrating drug delivery platform utilizing hyaluronic acid nanoparticles for cancer cell targeting and protease enzymes for degrading the tumor extracellular matrix to enable deep tissue penetration. It supports delivery of both small-molecule drugs (chemotherapy) and therapeutic cells (e.g., CAR-T cells).

MIGRA competes in the advanced drug delivery and tumor microenvironment modulation space, facing competition from larger biotechs and pharma with nanoparticle, antibody-drug conjugate (ADC), and stromal targeting programs. Its specific focus on protease-enabled stroma penetration for cell delivery is a niche but increasingly competitive area within immuno-oncology.